Personalized Cancer Therapy Prioritization Based on Driver Alteration Co-occurrence Patterns

Abstract excerpt

Identification of actionable genomic vulnerabilities is the cornerstone of precision oncology. Based on a large-scale drug screening in patient derived-xenografts, we uncover connections between driver gene alterations, derive Driver Co-Occurrence (DCO) networks, and relate these to drug sensitivity. Our collection of 53 drug response predictors attained an average balanced accuracy of 58% in a cross-validation se...

Topics

Open a Topic to create a Post that cites this publication.

• Algorithms
• Antineoplastic Agents
• Cell Line, Tumor
• CRISPR-Cas Systems
• Drug Discovery
• Genetic Testing
• Neoplasms
• Phenotype

Identifiers and source

Literature Corpus work

ff84c89f-6455-5b59-9bb1-064095a51091

DOI

10.1101/772673